Coya Therapeutics (COYA) investor relations material

Investment highlights and market opportunity

• Targeting high unmet needs in ALS, FTD, and Alzheimer's Disease with novel Treg-directed combination therapies.

• COYA 302 and COYA 303 offer differentiated approaches, with ongoing and planned Phase 2 studies in ALS and FTD.

• COYA 302 has a potential market opportunity exceeding $10B, supported by strong partnerships and a cash runway estimated at $50.7M through 2H 2027.

• Strategic collaborations include Dr. Reddy's ($700M in milestones, $10M investment) and ADDF ($5M for FTD trial).

Clinical programs and milestones

• ALSTARS Phase 2 study in ALS is active, with enrollment completion expected 2H 2026 and top-line data in 1Q 2027.

• Phase 2a study in FTD to initiate in 2H 2026, following IND acceptance in 1Q 2026.

• Ongoing translational and clinical datasets will provide insights into Treg biology, target engagement, and pathway modulation.

• Fast Track Designation granted to COYA 302 in ALS.

Scientific rationale and clinical validation

• Combination therapy with low-dose IL-2 and CTLA4-Ig is based on Nobel Prize-recognized Treg biology.

• Early clinical validation shows stabilization or improvement in ALSFRS-R scores in ALS and cognitive stability in FTD.

• Combination therapy restores Treg function and rebalances immune homeostasis, offering neuroprotection.